Jazz Pharmaceuticals
JAZZ
471 hedge funds and large institutions have $7.05B invested in Jazz Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 148 increasing their positions, 164 reducing their positions, and 56 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
7% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 56
0% more funds holding
Funds holding: 471 → 471 (0)
6% less call options, than puts
Call options by funds: $11.7M | Put options by funds: $12.4M
10% less repeat investments, than reductions
Existing positions increased: 148 | Existing positions reduced: 164
1.91% less ownership
Funds ownership: 90.46% → 88.56% (-1.9%)
15% less capital invested
Capital invested by funds: $8.31B → $7.05B (-$1.26B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$75M |
| 2 |
AC
Armistice Capital
New York
|
+$61.4M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$49.6M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$38.6M |
| 5 |
BlackRock
New York
|
+$30M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$84.9M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$63.4M |
| 3 |
JP Morgan Chase
New York
|
-$58M |
| 4 |
Janus Henderson Group
London,
|
-$48.5M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$37.8M |
JAZZ Hedge Fund Activity: Q2 2023 in Review
471 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2023, worth a combined $7.05B — down 15% from $8.31B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new JAZZ positions and 56 closed out — a net gain of 4 holders — while 148 added to existing stakes and 164 trimmed.
The largest buyer was Samlyn Capital, adding an estimated $75M. The largest seller was Millennium Management, cutting an estimated $84.9M.
- 471 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $7.05B of Jazz Pharmaceuticals stock for Q2 2023, down 15% quarter-over-quarter.
- 60 funds opened new Jazz Pharmaceuticals positions in Q2 2023 and 56 closed out, a net change of +4 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2023 was Samlyn Capital, an estimated $75M added.
- The largest Jazz Pharmaceuticals seller in Q2 2023 was Millennium Management, an estimated $84.9M sold.
Based on aggregated 13F filings for Q2 2023.